MedPath

Efficacy of gencydo nasal spray on early nasal response after allergen exposition in patients with grass pollen allergy, a randomized, placebo controlled cross over study

Phase 2
Conditions
J30.1
Allergic rhinitis due to pollen
Registration Number
DRKS00004312
Lead Sponsor
iversitätsklinikum Freiburg, Leitender ärztlicher Direktor
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
41
Inclusion Criteria

men and women aged between 18 - 50 years
-symptoms of grass polen allergy for at least 2 years (sneezing, itching of nose, running nose, tears)
-proof of allergy through prick test
-signed consent

Exclusion Criteria

•Chronic serious illness (i.e. diabetes mellitus type I, chronic polyarthritis, tumors, heart insufficiency, HIV-Infection)
•Asthma bronchiale with continuous therapy with inhalative or systemic steroides
•Hypersensitivity against compounds of Gencydo (quince, lemon)
•Treatment with Gencydo Nasal Spray within the last month before inclusion into the study
•Therapy with antihistamines, Cromoglycine acid, steroides or other antiallergic medication with 2 weeks before inclusion into the study
•anamnestic alcohol abuse >30g/d or iv. drug abuse
•pregnancy or breat feeding
•simultaneous participation in another clinical study within 3 months before inclusion into the study
• acute infection of airways or allergic reaction with distant symptoms

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
•Rhinomanometrically measured inspiratory nasal flow at 150 Pascal after provocation with grass pollen in an intraindividual comparison between Gencydo and placebo treatment
Secondary Outcome Measures
NameTimeMethod
Concentration of histamine in nasal lavage fluid after provocation with grass pollen in an intraindividual comparison between Gencydo and placebo
© Copyright 2025. All Rights Reserved by MedPath